NeRRe Therapeutics announces appointment of Ian Nicholson as Chief Business Officer

19 March 2014

UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, has announced the appointment of Ian Nicholson (pictured) as Chief Business Officer (CBO).

Mr Nicholson brings with him more than 25 years’ international experience within the life sciences sector, covering both management and transactions. He will be responsible for driving NeRRe’s business development strategy and providing commercial input into the company’s programmes.

Mr Nicholson has extensive experience of licensing, M&A, and global market development and has held senior positions with Chroma Therapeutics, Celltech, Oxford Asymmetry, Lonza AG and Amersham International.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK